TAK-285-分析测试百科网

溶解性	DMSO 110 mg/mL Water <1 mg/mL Ethanol 54 mg/mL
存贮条件	储存温度-20°C

备注	TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. Phase 1.
生化机理	TAK-285 is a novel dual HER2 and EGFR inhibitor with IC50 of 17 nM and 23 nM, respectively. A Phase I study of TAK-285 in patients with advanced cancer has been completed. TAK-285 is a novel, orally active, dual HER2/EGFR inhibitor with antitumor activity in mouse xenograft models, including breast, gastric, lung, and colon cancer.
别名	N-(2-(4-(3-chloro-4-(3-(trifluoromethyl)phenoxy)phenylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide;N-(2-(4-(3-chloro-4-(3-(trifluoromethyl)phenoxy)phenylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide